$2.47 Billion is the total value of Camber Capital Management LP's 34 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 47.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | New | SPDR S&P 500 ETF Trustput | $707,220,000 | – | 3,000,000 | +100.0% | 28.68% | – |
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)adr | $167,396,000 | -2.3% | 5,216,450 | +10.4% | 6.79% | -23.9% |
| MYL | MYLAN NV | $161,648,000 | +2.2% | 4,145,889 | 0.0% | 6.56% | -20.4% | |
| GILD | Buy | GILEAD SCIENCES, INC. | $129,048,000 | +20.1% | 1,900,000 | +26.7% | 5.23% | -6.4% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $126,738,000 | +72.2% | 5,400,000 | -10.0% | 5.14% | +34.1% |
| AGN | Sell | ALLERGAN PLC | $104,109,000 | -8.7% | 435,750 | -19.8% | 4.22% | -28.9% |
| MYGN | Buy | MYRIAD GENETICS INC | $83,040,000 | +22.7% | 4,325,000 | +6.5% | 3.37% | -4.4% |
| GHDX | GENOMIC HEALTH INC | $77,406,000 | +7.1% | 2,458,100 | 0.0% | 3.14% | -16.5% | |
| BKD | BROOKDALE SENIOR LIVING | $73,865,000 | +8.1% | 5,500,000 | 0.0% | 3.00% | -15.8% | |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $71,078,000 | +28.6% | 650,000 | -13.3% | 2.88% | +0.2% |
| GILD | GILEAD SCIENCES, INC.call | $67,920,000 | -5.2% | 1,000,000 | 0.0% | 2.76% | -26.1% | |
| SEM | Sell | SELECT MEDICAL HOLDINGS CORP | $66,750,000 | -16.4% | 5,000,000 | -17.0% | 2.71% | -34.9% |
| BIVV | New | BIOVERATIV INC | $59,906,000 | – | 1,100,000 | +100.0% | 2.43% | – |
| LIVN | LIVANOVA PLC | $58,812,000 | +9.0% | 1,200,000 | 0.0% | 2.38% | -15.1% | |
| OFIX | ORTHOFIX INTL N V | $57,225,000 | +5.4% | 1,500,000 | 0.0% | 2.32% | -17.9% | |
| ENDP | Buy | ENDO INTL PLC | $56,380,000 | -12.3% | 5,052,000 | +29.5% | 2.29% | -31.7% |
| PRGO | Sell | PERRIGO CO PLC | $53,656,000 | -46.6% | 808,200 | -33.1% | 2.18% | -58.4% |
| CSII | Sell | CARDIOVASCULAR SYSTEMS INC | $49,481,000 | -18.2% | 1,750,000 | -30.0% | 2.01% | -36.3% |
| ABT | ABBOTT LABS | $44,410,000 | +15.6% | 1,000,000 | 0.0% | 1.80% | -10.0% | |
| ELGX | Buy | ENDOLOGIX INC | $43,440,000 | +108.9% | 6,000,000 | +65.1% | 1.76% | +62.7% |
| ALKS | Sell | ALKERMES PLC | $42,413,000 | -23.7% | 725,000 | -27.5% | 1.72% | -40.6% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $39,960,000 | – | 1,350,000 | +100.0% | 1.62% | – |
| NVTA | INVITAE CORP | $26,523,000 | +39.3% | 2,398,123 | 0.0% | 1.08% | +8.5% | |
| ELOS | SYNERON MEDICAL LTD | $24,767,000 | +25.6% | 2,347,593 | 0.0% | 1.00% | -2.1% | |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $24,180,000 | – | 650,000 | +100.0% | 0.98% | – |
| BIOS | BIOSCRIP INC | $17,306,000 | +63.5% | 10,180,000 | 0.0% | 0.70% | +27.4% | |
| PTCT | New | PTC THERAPEUTICS | $12,300,000 | – | 1,250,000 | +100.0% | 0.50% | – |
| BIOL | BIOLASE INC | $7,199,000 | -3.6% | 5,332,394 | 0.0% | 0.29% | -24.9% | |
| ARNA | ARENA PHARMACEUTICALS INC | $6,205,000 | +2.8% | 4,250,000 | 0.0% | 0.25% | -19.7% | |
| ATRA | New | ATARA BIOTHERAPEUTICS INC | $2,569,000 | – | 125,000 | +100.0% | 0.10% | – |
| TARGACEPT INCnote | $1,685,000 | 0.0% | 1,684,799 | 0.0% | 0.07% | -22.7% | ||
| DXTRQ | DEXTERA SURGICAL INC. | $888,000 | +10.4% | 837,483 | 0.0% | 0.04% | -14.3% | |
| BIOL | BIOLASE INCcall | $0 | – | 1,841,173 | 0.0% | 0.00% | – | |
| CATB | Exit | CATABASIS PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -0.19% | – |
| Exit | PROTALIX BIO THERAPEUTICS, INCnote 4.500% 9/1 | $0 | – | -9,000,000 | -100.0% | -0.24% | – | |
| CNC | Exit | CENTENE CORPORATION | $0 | – | -200,000 | -100.0% | -0.59% | – |
| AMAG | Exit | AMAG PHARMACEUTICALS | $0 | – | -611,390 | -100.0% | -1.11% | – |
| ATHN | Exit | ATHENAHEALTH INC | $0 | – | -300,000 | -100.0% | -1.64% | – |
| CNMD | Exit | CONMED CORP COM | $0 | – | -750,000 | -100.0% | -1.72% | – |
| Exit | AMGEN INC | $0 | – | -300,000 | -100.0% | -2.28% | – | |
| UAM | Exit | UNIVERSAL AMERICAN CORPORATION | $0 | – | -4,875,000 | -100.0% | -2.53% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -175,000 | -100.0% | -2.58% | – |
| SYK | Exit | STRYKER CORPput | $0 | – | -1,000,000 | -100.0% | -6.24% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.